Literature DB >> 25765918

Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice.

Maria Cristina Tomasini1,2, Andrea Celeste Borelli3, Sarah Beggiato1,2, Luca Ferraro1,2,4, Tommaso Cassano5, Sergio Tanganelli2,3,4, Tiziana Antonelli2,3,4.   

Abstract

BACKGROUND: Considering the heterogeneity of pathological changes occurring in Alzheimer's disease (AD), a therapeutic approach aimed both to neuroprotection and to neuroinflammation reduction may prove effective. Palmitoylethanolamide (PEA) has attracted attention for its anti-inflammatory/neuroprotective properties observed in AD animal models. OBJECTIVE AND METHODS: We evaluated the protective role of PEA against amyloid-β₄₂ (Aβ₄₂) toxicity on cell viability and glutamatergic transmission in primary cultures of cerebral cortex neurons and astrocytes from the triple-transgenic murine model of AD (3xTg-AD) and their wild-type littermates (non-Tg) mice.
RESULTS: Aβ₄₂ (0.5 μM; 24 h) affects the cell viability in cultured cortical neurons and astrocytes from non-Tg mice, but not in those from 3xTg-AD mice. These effects were counteracted by the pretreatment with PEA (0.1 μM). Basal glutamate levels in cultured neurons and astrocytes from 3xTg-AD mice were lower than those observed in cultured cells from non-Tg mice. Aβ₄₂-exposure reduced and increased glutamate levels in non-Tg mouse cortical neurons and astrocytes, respectively. These effects were counteracted by the pretreatment with PEA. By itself, PEA did not affect cell viability and glutamate levels in cultured cortical neurons and astrocytes from non-Tg or 3xTg-AD mice.
CONCLUSION: The exposure to Aβ₄₂ induced toxic effects on cultured cortical neurons and astrocytes from non-Tg mice, but not in those from 3xTg-AD mice. Furthermore, PEA exerts differential effects against Aβ₄₂-induced toxicity in primary cultures of cortical neurons and astrocytes from non-Tg and 3xTg-AD mice. In particular, PEA displays protective properties in non-Tg but not in 3xTg-AD mouse neuronal cultured cells overexpressing Aβ.

Entities:  

Keywords:  Alzheimer’s disease; GFAP immunoreactivity; MAP2 immunoreactivity; cell viability; glutamate

Mesh:

Substances:

Year:  2015        PMID: 25765918     DOI: 10.3233/JAD-143039

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  12 in total

Review 1.  Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.

Authors:  Eugenia Landolfo; Debora Cutuli; Laura Petrosini; Carlo Caltagirone
Journal:  Biomolecules       Date:  2022-05-05

2.  Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence.

Authors:  Maria Rosanna Bronzuoli; Roberta Facchinetti; Luca Steardo; Adele Romano; Claudia Stecca; Sergio Passarella; Luca Steardo; Tommaso Cassano; Caterina Scuderi
Journal:  Oxid Med Cell Longev       Date:  2018-01-16       Impact factor: 6.543

3.  Heme oxygenase-1 derived carbon monoxide suppresses Aβ1-42 toxicity in astrocytes.

Authors:  Nishani T Hettiarachchi; John P Boyle; Mark L Dallas; Moza M Al-Owais; Jason L Scragg; Chris Peers
Journal:  Cell Death Dis       Date:  2017-06-15       Impact factor: 8.469

4.  In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5.

Authors:  Sarah Beggiato; Andrea C Borelli; Maria C Tomasini; M Paola Castelli; Nicholas Pintori; Roberto Cacciaglia; Antonella Loche; Luca Ferraro
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

5.  Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin.

Authors:  Roberta Facchinetti; Marta Valenza; Maria Rosanna Bronzuoli; Giorgia Menegoni; Patrizia Ratano; Luca Steardo; Patrizia Campolongo; Caterina Scuderi
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 6.  Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease.

Authors:  Sarah Beggiato; Maria Cristina Tomasini; Luca Ferraro
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

7.  Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease.

Authors:  Sarah Beggiato; Maria Cristina Tomasini; Tommaso Cassano; Luca Ferraro
Journal:  J Clin Med       Date:  2020-02-05       Impact factor: 4.241

Review 8.  Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy.

Authors:  Jan M Keppel Hesselink; Ciro Costagliola; Josiane Fakhry; David J Kopsky
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

9.  Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.

Authors:  Caterina Scuderi; Maria Rosanna Bronzuoli; Roberta Facchinetti; Lorenzo Pace; Luca Ferraro; Kevin Donald Broad; Gaetano Serviddio; Francesco Bellanti; Gianmauro Palombelli; Giulia Carpinelli; Rossella Canese; Silvana Gaetani; Luca Steardo; Luca Steardo; Tommaso Cassano
Journal:  Transl Psychiatry       Date:  2018-01-31       Impact factor: 6.222

10.  Partial Reversal of Striatal Damage by Palmitoylethanolamide Administration Following Perinatal Asphyxia.

Authors:  Lucas D Udovin; Tamara Kobiec; María I Herrera; Nicolás Toro-Urrego; Carlos F Kusnier; Rodolfo A Kölliker-Frers; Ana B Ramos-Hryb; Juan P Luaces; Matilde Otero-Losada; Francisco Capani
Journal:  Front Neurosci       Date:  2020-01-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.